Xencor to Present at Upcoming Investor Conferences

Rhea-AI Summary

Xencor, a clinical-stage biopharmaceutical company focused on engineered monoclonal antibodies and cytokines for treating cancer and autoimmune diseases, has announced its participation in several investor events.

• Bernstein CD28 Day: Presentation on August 9 at 1:00 p.m. ET.
• Wedbush PacGrow Healthcare Conference: Panel on August 10 at 1:10 p.m. ET.
• BTIG Virtual Biotechnology Conference: Presentation on August 10 at 3:30 p.m. ET.
• Canaccord Genuity Conference: Presentation on August 11 at 4:30 p.m. ET.
• Piper Sandler West Coast Bus Tour: Presentation on August 12 at 4:00 p.m. ET.

A webcast of the Canaccord presentation will be available on Xencor's website.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate in the following upcoming investor events and conferences:

• Bernstein CD28 Day
  Presentation: Monday, August 9, 1:00 p.m. ET (10:00 a.m. PT)

• 2021 Wedbush PacGrow Healthcare Virtual Conference
  Panel: Tuesday, August 10, 1:10 p.m. ET (10:10 a.m. PT)

• BTIG Virtual Biotechnology Conference 2021
  Presentation: Tuesday, August 10, 3:30 p.m. ET (12:30 p.m. PT)

• Canaccord Genuity 41st Annual Growth Conference
  Presentation: Wednesday, August 11, 4:30 p.m. ET (1:30 p.m. PT)

• Piper Sandler Virtual West Coast Bus Tour
  Presentation: Thursday, August 12, 4:00 p.m. ET (1:00 p.m. PT)

A webcast of the presentation at the Canaccord conference will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. Following the webcast, a replay will be archived on the website approximately for at least 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 22 candidates engineered with Xencor's XmAb^® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210802005699/en/

FAQ

What are the upcoming investor events for XNCR?

Xencor will participate in several investor events, including Bernstein CD28 Day on August 9, Wedbush PacGrow Conference on August 10, BTIG Virtual Conference on August 10, Canaccord Genuity Conference on August 11, and Piper Sandler West Coast Bus Tour on August 12.

When is the presentation at the Canaccord Genuity Conference for XNCR?

The presentation at the Canaccord Genuity 41st Annual Growth Conference is scheduled for August 11 at 4:30 p.m. ET.

Where can I watch the XNCR webcast from the Canaccord conference?

The webcast of the presentation at the Canaccord conference will be available on Xencor's website under 'Events & Presentations' in the Investors section.

How many candidates does XNCR have in clinical development?

Xencor currently has 22 candidates in clinical development, utilizing their XmAb technology for new therapeutic actions.